Quinazolinone-type compounds as CRTH
View Patent ↗This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTH 2 receptor.
1. A compound for the formula:
or a pharmaceutically acceptable salt thereof
wherein:
X is a bond or —S(O) m —;
Y is selected from the group consisting of:
a) a bond, —O—, —NH—, —N(R 9 )— or —N(COR 9 )—;
where
A is —O—, —S— or N(R)—;
B is —C— or —N—;
a is 0, 1, 2, or 3;
r is 0, 1 or 2;
s is 0, 1 or 2;
R is H, alkyl or haloalkyl;
R a is independently H, halo, alkyl or haloalkyl;
R b is independently H, halo, alkyl or haloalkyl;
R 1 is heteroaryl, heterocyclyl or heterocyclenyl;
R 2 is aryl, heteroaryl, alkyl or heterocyclyl;
R 3 is —C(O)OH or —N(H)—SO 2 —R c ;
where:
R c is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl;
R 4 is independently selected from the group consisting of alkyl, —OH, halo, alkoxy, haloalkoxy, —CN and haloalkyl;
R 8 is independently selected from the group consisting of —CN, halo, alkyl, haloalkyl, alkoxy, haloalkoxy and cycloalkyl;
R 9 is alkyl, haloalkyl, alkoxy, haloalkoxy or cycloalkyl;
and wherein:
i) the heteroaryl, heterocyclyl or heterocyclenyl group in R 1 ; and
ii) each of the aryl, heteroaryl, alkyl or heterocyclyl groups of R 2 ; are independently unsubstituted or substituted by 1 to 5 R 5 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , —CH 2 OSi(R 14 )(R 15 )(R 16 , —OR 14 , —C(O)R 14 , —C(O)OR 14 , —O—C(O)—R 14 , —O—C(O)N(R 14 )(R 15 ), —C(O)N(R 14 )(R 15 ), —S(O) m R 14 , —S(O) p N(R 14 )(R 15 ), —C(═NOR 14 )R 15 , —N(R 14 )(R 15 ), —N(R 14 )C(O)R 15 , —N(R 14 )S(O) p R 15 , —N(R 14 )S(O) p N(R 15 )(R 16 ), —N(R 14 )C(O)N(R 15 )(R 16 ) and —N(R 14 )C(O)OR 16 ;
or when a position is disubstituted by two R 5 groups, the two R 5 groups can form a cycloalkyl or heterocyclyl ring that is unsubstituted or is substituted by 1 to 5 R 6 groups;
and wherein:
each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl groups in R 5 are independently unsubstituted or substituted by 1 to 5 R 6 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , —CH 2 OSi(R 14 )(R 15 )(R 16 ), —OR 14 , —C(O)R 14 , —C(O)OR 14 , —O—C(O)—R 14 , —O—C(O)—N(R 14 )(R 15 ), —C(O)N(R 14 )(R 15 ), —S(O) m R 14 , —S(O) p N(R 14 )(R 15 ), —C(═NOR 14 )R 15 , —N(R 14 )(R 15 ), —N(R 14 )C(O)R 15 ; —N(R 14 )S(O) p R 15 , —N(R 14 )S(O) p N(R 15 )(R 16 ), —N(R 14 )C(O)N(R 15 )(R 16 ); —N(R 14 )C(O)OR 16 and —N(R 14 )C(O)R 16 ; and
wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl groups in R 6 are independently unsubstituted or substituted by 1 to 5 R 7 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , —CH 2 OSi(R 14 )(R 15 )(R 16 ), —OR 14 , —C(O)R 14 , —C(O)OR 14 , —O—C(O)—R 14 , —O—C(O)—N(R 14 )(R 15 ), —C(O)N(R 14 )(R 15 ), —S(O) m R 14 , —S(O) p N(R 14 )(R 15 ), —C(═NOR 14 )R 15 , —N(R 14 )(R 15 ), —N(R 14 )C(O)R 15 , —N(R 14 )S(O) p R 15 , —N(R 14 )S(O) p N(R 15 )(R 16 ), —N(R 14 )C(O)N(R 15 )(R 16 ); —N(R 14 )C(O)OR 16 and —N(R 14 )C(O)R 16 ;
wherein:
R 14 , R 15 and R 16 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, R 17 -alkyl, R 17 -alkenyl, R 17 -alkynyl, R 17 -cycloalkyl, R 17 -cycloalkenyl, R 17 -heterocyclyl, R 17 -heterocyclenyl, R 17 -aryl, and R 17 -heteroaryl;
R 17 is 1-5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, halo-substituted aryl, nitrile-substituted aryl, phenyl-substituted aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , heteroaryl, haloalkyl, —C(O)R 18 , —C(O)OH, —C(O)OR 18 , —C(O)NHR 19 , —C(O)NH 2 , —C(O)N(R 18 )(R 19 ), —S(O) m R 18 , —S(O) p NH 2 , —S(O)NH p (alkyl), —S(O) p N(alkyl)(alkyl), —S(O) p NH(aryl), —S(O) 2 NHR 19 , —S(O) 2 NH(heterocycloalkyl), —S(O) 2 N(alkyl)(aryl), haloalkoxy, —OH, —OR 19 , —O-heterocycloalkyl, —O-cycloalkylalkyl, —O-heterocyclylalkyl, —NH 2 , —NHR 19 , —N(alkyl) 2 , —N(arylalkyl) 2 , —N(arylalkyl)-(heteroarylalkyl), —NHC(O)R 19 , —NHC(O)NH 2 , —NHC(O)NH(alkyl), —NHC(O)N(alkyl)(alkyl), —N(alkyl)C(O)NH(alkyl), —N(alkyl)C(O)N(alkyl)(alkyl), —NHS(O) 2 R 21 , —NHS(O) 2 NH(alkyl), —NHS(O) 2 N(alkyl)(alkyl), —N(alkyl)S(O) 2 NH(alkyl) and —N(alkyl)S(O) 2 N(alkyl)(alkyl);
R 18 is alkyl, cycloalkyl, aryl, arylalkyl or heteroarylalkyl;
R 19 is alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl, heteroaryl or heteroarylalkyl;
R 21 is alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl, heteroaryl or heteroarylalkyl;
b is 0, 1 or 2;
n is an integer from 1 to 5;
m is independently an integer from 0 to 2;
p is an integer from 1 to 2;
q is an integer from 0 to 5;
wherein
each heteroaryl is independently an aromatic monocyclic or bicyclic ring system comprising 5 to 14 ring atoms, wherein one or more of the ring atoms is nitrogen, oxygen, or sulfur,
each heterocyclyl is independently a non-aromatic saturated monocyclic or multicyclic ring system comprising 3 to 12 ring atoms, wherein one or more of the ring atoms is nitrogen, oxygen, or sulfur; and
each heterocyclenyl is independently a non-aromatic monocyclic or multicyclic ring system comprising 3 to 10 ring atoms, wherein one or more of the ring atoms is nitrogen, oxygen, or sulfur; and wherein the heterocyclenyl contains at least one carbon-carbon double bond or carbon-nitrogen double bond.
2. The compound according to claim 1 which has the formula:
or a pharmaceutically acceptable salt thereof
wherein:
Y is selected from the group consisting of:
a) a bond;
where
A is —O—, —S— or N(R)—;
B is —C— or —N—;
a is 0, 1, 2, or 3;
r is 0, 1 or 2;
s is 0, 1 or 2;
R is H, alkyl or haloalkyl;
R a is independently H, halo, alkyl or haloalkyl
R b is independently H, halo, alkyl or haloalkyl;
R 1 is heteroaryl, heterocyclyl or heterocyclenyl;
R 2 is aryl, heteroaryl, alkyl or heterocyclyl;
R 3 is —C(O)OH or —N(H)—SO 2 —R c ;
where:
R c is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl;
R 4 is independently selected from the group consisting of alkyl, —OH, halo, alkoxy, haloalkoxy, —CN and haloalkyl;
R 8 is independently selected from the group consisting of —CN, halo, alkyl, haloalkyl, alkoxy, haloalkoxy and cycloalkyl;
and wherein:
i) the heteroaryl heterocyclyl or heterocyclenyl group in R 1 ; and
ii) each of the aryl, heteroaryl, alkyl or heterocyclyl groups of R 2 ; are independently unsubstituted or substituted by 1 to 5 R 5 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , —CH 2 OSi(R 14 )(R 15 )(R 16 ), —OR 14 , —C(O)R 14 , —C(O)OR 14 , —O—C(O)—R 14 , —O—C(O)N(R 14 )(R 15 ), —C(O)N(R 14 )(R 15 ), —S(O) m R 14 , —S(O) p N(R 14 )(R 15 ), —C(═NOR 14 )R 15 , —N(R 14 )(R 15 ), —N(R 14 )C(O)R 15 , —N(R 14 )S(O) p R 15 , —N(R 14 )S(O) p N(R 15 )(R 16 ), —N(R 14 )C(O)N(R 15 )(R 16 ) and —N(R 14 )C(O)OR 16 ;
or when a position is disubstituted by two R 5 groups, the two R 5 groups can form a cycloalkyl or heterocyclyl ring that is unsubstituted or is substituted by 1 to 5 R 6 groups
and wherein:
each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl groups in R 5 are independently unsubstituted or substituted by 1 to 5 R 6 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , —CH 2 OSi(R 14 )(R 15 )(R 16 ), —OR 14 , —C(O)R 14 , —C(O)OR 14 , —O—C(O)—R 14 , —O—C(O)—N(R 14 )(R 15 ), —C(O)N(R 14 )(R 15 ), —S(O) m R 14 , —S(O) p N(R 14 )(R 15 ), —C(═NOR 14 )R 15 , —N(R 14 )(R 15 ), —N(R 14 )C(O)R 15 , —N(R 14 )S(O) p R 15 , —N(R 14 )S(O) p N(R 15 )(R 16 ), —N(R 14 )C(O)N(R 15 )(R 16 ); —N(R 14 )C(O)OR 16 and —N(R 14 )C(O)R 16 ; and
wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl groups in R 6 are independently unsubstituted or substituted by 1 to 5 R 7 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , —CH 2 OSi(R 14 )(R 15 )(R 16 ), —OR 14 , —C(O)R 14 , —C(O)OR 14 , —O—C(O)—R 14 , —O—C(O)—N(R 14 )(R 15 ), —C(O)N(R 14 )(R 15 ), —S(O) m R 14 , —S(O) p N(R 14 )(R 15 ), —C(═NOR 14 )R 15 , —N(R 14 )(R 15 ), —N(R 14 )C(O)R 15 , —N(R 14 )S(O) p R 15 , —N(R 14 )S(O) p N(R 15 )(R 16 ), —N(R 14 )C(O)N(R 15 )(R 16 ); —N(R 14 )C(O)OR 16 and —N(R 14 )C(O)R 16 ;
wherein:
R 14 , R 15 and R 16 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, R 17 -alkyl, R 17 -alkenyl, R 17 -alkynyl, R 17 -cycloalkyl, R 17 -cycloalkenyl, R 17 -heterocyclyl, R 17 -heterocyclenyl, R 17 -aryl, and R 17 -heteroaryl;
R 17 is 1-5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , heteroaryl, haloalkyl, —C(O)R 18 , —C(O)OH, —C(O)OR 18 , —C(O)NHR 19 , —C(O)NH 2 , —C(O)N(R 18 )(R 19 ), —S(O) m R 18 , —S(O) p NH 2 , —S(O)NH p (alkyl), —S(O) p N(alkyl)(alkyl), —S(O) p NH(aryl), —S(O) 2 NHR 19 , —S(O) 2 NH(heterocycloalkyl), —S(O) 2 N(alkyl)(aryl), haloalkoxy, —OH, —OR 19 , —O-heterocycloalkyl, —O-cycloalkylalkyl, —O-heterocyclylalkyl, —NH 2 , —NHR 19 , —N(alkyl) 2 , —N(arylalkyl) 2 , —N(arylalkyl)-(heteroarylalkyl), —NHC(O)R 19 , —NHC(O)NH 2 , —NHC(O)NH(alkyl), —NHC(O)N(alkyl)(alkyl), —N(alkyl)C(O)NH(alkyl), —N(alkyl)C(O)N(alkyl)(alkyl), —NHS(O) 2 R 21 , —NHS(O) 2 NH(alkyl), —NHS(O) 2 N(alkyl)(alkyl), —N(alkyl)S(O) 2 NH(alkyl) and —N(alkyl)S(O) 2 N(alkyl)(alkyl);
R 18 is alkyl, cycloalkyl, aryl, arylalkyl or heteroarylalkyl;
R 19 is alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl, heteroaryl or heteroarylalkyl;
R 21 is alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl, heteroaryl or heteroarylalkyl;
b is 0, 1 or 2;
n is an integer from 1 to 5;
m is independently an integer from 0 to 2;
p is an integer from 1 to 2; and
q is an integer from 0 to 5.
3. The compound of claim 1 which has the formula:
or a pharmaceutically acceptable salt thereof
wherein:
Y is selected from the group consisting of:
a) a bond;
where
A is —O—, —S— or N(R)—;
B is —C— or —N—;
a is 0, 1, 2, or 3;
r is 0, 1 or 2; and
s is 0, 1 or 2;
R is H, alkyl or haloalkyl;
R a is independently H, halo, alkyl or haloalkyl
R b is independently H, halo, alkyl or haloalkyl;
R 1 is heteroaryl, heterocyclyl or heterocyclenyl;
R 2 is aryl, heteroaryl, alkyl or heterocyclyl;
R 3 is —C(O)OH or —N(H)—SO 2 —R c ;
where:
R c is alkyl, haloalkyl, cycloalkyl, aryl or heteroaryl;
R 4 is independently selected from the group consisting of alkyl, —OH, halo, alkoxy, haloalkoxy, —CN and haloalkyl;
R 8 is independently selected from the group consisting of —CN, halo, alkyl, haloalkyl, alkoxy, haloalkoxy and cycloalkyl;
and wherein:
i) the heteroaryl, heterocyclyl or heterocyclenyl group in R 1 ; and
ii) each of the aryl, heteroaryl, alkyl or heterocyclyl groups of R 2 ; are independently unsubstituted or substituted by 1 to 5 R 5 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , —CH 2 OSi(R 14 )(R 15 )(R 16 ), —OR 14 , —C(O)R 14 , —C(O)OR 14 , —O—C(O)—R 14 , —O—C(O)N(R 14 )(R 15 ), —C(O)N(R 14 )(R 15 ), —S(O) m R 14 , —S(O) p N(R 14 )(R 15 ), —C(═NOR 14 )R 15 , —N(R 14 )(R 15 ), —N(R 14 )C(O)R 15 , —N(R 14 )S(O) p R 15 , —N(R 14 )S(O) p N(R 15 )(R 16 ), —N(R 14 )C(O)N(R 15 )(R 16 ) and —N(R 14 )C(O)OR 16 ;
or when a position is disubstituted by two R 5 groups, the two R 5 groups can form a cycloalkyl or heterocyclyl ring that is unsubstituted or is substituted by 1 to 5 R 6 groups
and wherein:
each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl groups in R 5 are independently unsubstituted or substituted by 1 to 5 R 6 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , —CH 2 OSi(R 14 )(R 15 )(R 16 ), —OR 14 , —C(O)R 14 , —C(O)OR 14 , —O—C(O)—R 14 , —O—C(O)—N(R 14 )(R 15 ), —C(O)N(R 14 )(R 15 ), —S(O) m R 14 , —S(O) p N(R 14 )(R 15 ), —C(═NOR 14 )R 15 , —N(R 14 )(R 15 ), —N(R 14 )C(O)R 15 , —N(R 14 )S(O) p R 15 , —N(R 14 )S(O) p N(R 15 )(R 16 ), —N(R 14 )C(O)N(R 15 )(R 16 ); —N(R 14 )C(O)OR 16 and —N(R 14 )C(O)R 16 ; and
wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl groups in R 6 are independently unsubstituted or substituted by 1 to 5 R 7 groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , —CH 2 OSi(R 14 )(R 15 )(R 16 ), —OR 14 , —C(O)R 14 , —C(O)OR 14 , —O—C(O)—R 14 , —O—C(O)—N(R 14 )(R 15 ), —C(O)N(R 14 )(R 15 ), —S(O) m R 14 , —S(O) p N(R 14 )(R 15 ), —C(═NOR 14 )R 15 , —N(R 14 )(R 15 ), —N(R 14 )C(O)R 15 , —N(R 14 )S(O) p R 15 , —N(R 14 )S(O) p N(R 15 )(R 16 ), —N(R 14 )C(O)N(R 15 )(R 16 ); —N(R 14 )C(O)OR 16 and —N(R 14 )C(O)R 16 ;
wherein:
R 14 , R 15 and R 16 are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, R 17 -alkyl, R 17 -alkenyl, R 17 -alkynyl, R 17 -cycloalkyl, R 17 -cycloalkenyl, R 17 -heterocyclyl, R 17 -heterocyclenyl, R 17 -aryl, and R 17 -heteroaryl;
R 17 is 1-5 substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocyclyl, heterocyclenyl, aryl, heteroaryl, halo, —CN, —SF 5 , —OSF 5 , —NO 2 , heteroaryl, haloalkyl, —C(O)R 18 , —C(O)OH, —C(O)OR 18 , —C(O)NHR 19 , —C(O)NH 2 , —C(O)N(R 18 )(R 19 ), —S(O) m R 18 , —S(O) p NH 2 , —S(O)NH p (alkyl), —S(O) p N(alkyl)(alkyl), —S(O) p NH(aryl), —S(O) 2 NHR 19 , —S(O) 2 NH(heterocycloalkyl), —S(O) 2 N(alkyl)(aryl), haloalkoxy, —OH, —OR 19 , —O-heterocycloalkyl, —O-cycloalkylalkyl, —O-heterocyclylalkyl, —NH 2 , —NHR 19 , —N(alkyl) 2 , —N(arylalkyl) 2 , —N(arylalkyl)-(heteroarylalkyl), —NHC(O)R 19 , —NHC(O)NH 2 , —NHC(O)NH(alkyl), —NHC(O)N(alkyl)(alkyl), —N(alkyl)C(O)NH(alkyl), —N(alkyl)C(O)N(alkyl)(alkyl), —NHS(O) 2 R 21 , —NHS(O) 2 NH(alkyl), —NHS(O) 2 N(alkyl)(alkyl), —N(alkyl)S(O) 2 NH(alkyl) and —N(alkyl)S(O) 2 N(alkyl)(alkyl);
R 18 is alkyl, cycloalkyl, aryl, arylalkyl or heteroarylalkyl;
R 19 is alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl, heteroaryl or heteroarylalkyl;
R 21 is alkyl, cycloalkyl, aryl, halo substituted aryl, arylalkyl, heteroaryl or heteroarylalkyl;
b is 0, 1 or 2
n is an integer from 1 to 5;
m is independently an integer from 0 to 2;
p is an integer from 1 to 2; and
q is an integer from 0 to 5.
4. The compound of claim 2 , which has the structural formula:
or a pharmaceutically acceptable salt thereof
wherein:
R 1 is heteroaryl or R 5 -heteroaryl, wherein the heteroaryl ring is a ring selected from the group consisting of thiazole, oxazole, imidazole, 1,2-diazole, triazole, pyridine, pyrimidine, thiophene and furan, isooxazole, isothiazole and oxadiazole;
R 5 is 1 to 5 substituents independently selected from the group consisting of —C 1 -C 5 -alkyl, halogen, —C 1 -C 5 -haloalkyl, —C 1 -C 5 -alkoxy, —C 1 -C 5 , haloalkoxy, aryl, R 6 -aryl, —C 1 -C 5 alkyl-aryl and —C 1 -C 5 -alkyl-aryl-R 7
R 6 is 1 to 5 substituents independently selected from the group consisting of —C 1 -C 5 -alkyl, halogen, —CN, —C 1 -C 5 -haloalkyl, —OH or —C 1 -C 5 -alkoxy and —S(O) 2 alkyl;
R 7 is 1 to 5 substituents independently selected from the group consisting of —C 1 -C 5 -alkyl, halogen, —CN, —C 1 -C 5 -haloalkyl, —OH or —C 1 -C 5 -alkoxy and —S(O) 2 alkyl;
Z is halogen; and
n is 1 or 2.
5. The compound of claim 3 , which has the formula:
or a pharmaceutically acceptable salt thereof
wherein:
R 1 is heteroaryl or R 5 -heteroaryl, wherein the heteroaryl ring is a ring selected from the group consisting of thiazole, oxazole, imidazole, 1,2-diazole, triazole, pyridine, pyrimidine, thiophene, furan, isooxazole, isothiazole and oxadiazole;
R 5 is 1 to 5 substituents independently selected from the group consisting of —C 1 -C 5 -alkyl, halogen, —C 1 -C 5 -haloalkyl, C 1 -C 5 - alkoxy, —C 1 -C 5 -haloalkoxy, aryl, R 6 -aryl —C 1 -C 5 -alkyl-aryl and —C 1 -C 5 alkyl-aryl-R 7
R 6 is 1 to 5 substituents independently selected from the group consisting of —C 1 -C 5 -alkyl, halogen, —CN, —C 1 -C 5 -haloalkyl, —OH or —C 1 -C 5 -alkoxy and —S(O) 2 alkyl;
R 7 is 1 to 5 substituents independently selected from the group consisting of —C 1 -C 5 -alkyl, halogen, —CN, —C 1 -C 5 -haloalkyl, —OH or —C 1 -C 5 -alkoxy and —S(O) 2 alkyl;
Z is halogen; and
n is 3 or 4.
6. The compound of claim 3 , which has the formula:
or a pharmaceutically acceptable salt thereof
wherein:
R 5 -heterocyclenyl, wherein the heterocyclenyl ring is a ring selected from the group consisting of 4,5-dihydro-isoxazole, 1,2,3,4-tetrahydropyridinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, 1,2,3,6-tetrahydropyridinyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, and dihydrothiopyranyl;
R 5 is 1 to 5 substituents independently selected from the group consisting of —C 1 -C 5 -alkyl, halogen, —C 1 -C 5 -haloalkyl, —C 1 -C 5 -alkoxy, —C 1 -C 5 -haloalkoxy, aryl, R 6 -aryl, —C 1 -C 5 -alkyl-aryl and —C 1 -C 5 -alkyl-aryl-R 7
R 6 is 1 to 5 substituents independently selected from the group consisting of —C 1 -C 5 -alkyl, halogen, —CN, —C 1 -C 5 -haloalkyl, —OH, —C 1 -C 5 -alkoxy and —S(O) 2 alkyl;
R 7 is 1 to 5 substituents independently selected from the group consisting of —C 1 -C 5 -alkyl, halogen, —CN, —C 1 -C 5 -haloalkyl, —OH and —C 1 -C 5 -alkoxy and —S(O) 2 alkyl;
Z is halogen; and
n is 3 or 4.
7. The compound of claim 1 , which has the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
Z is a H or a halogen;
R 1 is R 5 -heterocyclenyl, wherein the heterocyclenyl ring is a ring selected from the group consisting of 4,5-dihydro-isoxazole, 1,2,3,4-tetrahydropyridinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, 1,2,3,6-tetrahydropyridinyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolinyl, 2-pyrazolinyl, dihydroimidazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, and dihydrothiopyranyl;
R 5 is 1 to 2 substituents independently selected from the group consisting of —C 1 -C 5 -alkyl, —C 1 -C 5 -haloalkyl, C 1 -C 5 - alkoxy, —C 1 -C 5 -haloalkoxy, aryl, R 6 -aryl, —C 1 -C 5 , alkyl-aryl-R 7 , heteroaryl and R 6 -heteroaryl: and
where R 6 and R 7 at each occurrence independently are —C 1 -C 5 -alkyl, halogen, —CN, —C 1 -C 5 -haloalkyl, —OH, —C 1 -C 5 -alkoxy or —S(O) 2 — C 1 -C 5 -alkyl.
8. The compound of claim 1 , which has the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
Z is H, Cl or F;
R 5a is phenyl, benzoxazole, benzothiazole, benzimidazole, imidazo[1,2-a]pyridine, pyrazolo[1,5-a]pyridine, and quinoxaline;
wherein R 5a is unsubstituted or substituted by 1 to 2 R 6 groups independently selected from the group consisting of C 1 -C 3 -alkyl, halo, CF 3 , and —CN; and
wherein R 5b is absent or present, and if present, is CH 3 .
9. The compound of claim 1 , which has the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
Z is H, Cl or F and
R 6a is phenyl, wherein the phenyl of R 6a is unsubstituted or substituted by 1 to 2 R 7 groups independently selected from the group consisting of halo, C 1 -C 3 alkyl, and —CN; and
wherein R 6b is absent or present, and, if present, is selected from the group consisting of —CH 3 and —OH.
10. The compound of claim 1 , which has the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
Z is H, Cl or F;
Q is C(H) or N;
R 6a is selected from the group consisting of:
(a) -M-E; and
(b) -E;
wherein M is selected from the group consisting of —N(H)S(O)—, —N(H)C(O)—, —S—, —S(O)—, —S—, and —OCH 2 —;
E is selected from the group consisting of:
(i) C 1 -C 3 -alkyl;
(ii) —O—(C 1 -C 4 -alkyl);
(iii) an aryl selected from the group consisting of phenyl and napthalene;
(iv) a heteroaryl selected from the group consisting of quinoline, quinoxaline, and benzimidazole; and
(v) 2,3-dihydroindole;
wherein said aryl or heteroaryl of E is unsubstituted or substituted by 1 to 3 moieties selected from the group consisting of C 1 -C 6 -alkyl, halo, CF 3 , OCF 3 , CN, OCH 3 , and phenyl;
R 6b is H, OH, or OCH 3 ; and
R 6c is H, C 1 -C 3 -alkyl, or CF 3 ;
or alternatively, R 6b and R 6c together with the carbon atom to which they are attached form —C(O)— or —C(═CH 2 )—.
11. The compound according to claim 1 or a pharmaceutically acceptable salt thereof which is selected from the group consisting of:
12. A pharmaceutical composition comprising an effective amount of a compound of Formula I according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
13. The pharmaceutical composition according to claim 12 which further comprises an effective amount of a leukotriene antagonist selected from the group consisting of montelukast, zafirlukast, and pranlukast.
14. A method for treating asthma, or allergic rhinitis, comprising administering an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.
15. The compound of claim 1 which is
or a pharmaceutically acceptable salt thereof.
16. The method of claim 14 , wherein the mammal is in need of treatment for asthma.